- $394.95m
- -$58.86m
- $97.67m
- 51
- 30
- 45
- 37
Annual cashflow statement for Somalogic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -57 | -53 | -87.5 | -109 |
| Depreciation | ||||
| Non-Cash Items | 17.4 | 30.5 | 43.1 | -23.3 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -14.1 | -8.67 | 4.93 | 27.2 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -50.5 | -28.3 | -37 | -101 |
| Capital Expenditures | -0.68 | -1.16 | -6.73 | -5.21 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 31.3 | -8.38 | -179 | 87.8 |
| Acquisition of Business | ||||
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | 30.7 | -9.54 | -185 | 82.5 |
| Financing Cash Flow Items | 0 | 5 | 530 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.144 | 189 | 497 | 5.18 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -19.7 | 151 | 275 | -13 |